Attorneys eyeing lawsuits over Zantac may be divided on the significance of the U.S. Food and Drug Administration’s decision calling on drugmakers to pull the heartburn medication from the market, but all agree the move highlights what appears to be a growing unease over the safety of the medication.
On Wednesday, the regulatory body announced it was requesting manufacturers to withdraw all prescription and over-the-counter Zantac from the market over concerns that a potentially carcinogenic molecule in the drug may build up over time if the medication is stored above room temperature. According to a press release issued Wednesday, the move is part of an ongoing investigation into the molecule N-Nitrosodimethylamine, or NDMA, which is a component of the drug.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Not a Bloomberg Law Subscriber?
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]